DEBM_CompanyBanner_ResearchManu_LG

Manufacturing, Research & Development


drug modeling
formulation &
manufacturing

Business

What we do

We are a pharmaceutical research, development and production facility, inspected and registered with the main regulatory authorities.

Business model

The Company is a world leader in polylactic-co-glycolic acid (PLGA)-based injectable, sustained-release technology. It has been used for one of our best-selling product Decapeptyl®, a novel injectable controlled-release formulation of triptorelin – a gonadotropin releasing hormone (GnRH) agonist analogue. This mode of administration developed by Debiopharm  Research & Manufacturing relies on the active substance being “encapsulated” in a PLGA polymer to allow gradual dissolution and distribution of the substance in the patient’s body.

The Company has succeeded in producing

  • 1-month,
  • 3-month and
  • 6-month sustained-release (SR) formulations.

It is also focusing on nanoparticular drug delivery systems.

Debiopharm-Cédric-Sager
Management

Discover the members who guide and bring long-term vision to the company

Discover
Contact us

Got a question or a comment? Get in touch

Contact us